...Good morning, and thank you for joining us to discuss the KT-621 Phase 1 Healthy Volunteer Results. I'm Justine Koenigsberg, Head of Investor Relations at Kymera. Joining me this morning with prepared remarks are Nello Mainolfi, our Founder, President and CEO; and Jared Gollob, our Chief Medical Officer. For today's discussion, Nello will begin with an overview of our immunology strategy and the opportunity with small molecule degraders. Then Jared will walk you through the KT-621 Phase 1 trial and results. Following our prepared remarks, we will open the call to questions where we will also be joined by Bruce Jacobs, our Chief Financial Officer. (Event Instructions) A replay of today's event, including the corresponding presentation, will be available soon after the call concludes in the Investors section of our website. But before we begin, I would like to remind you that today's discussion will include forward-looking statements about our future expectations, plans and prospects. These...
